If you have been reading about melanocortin receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-22. Numbers and descriptions here follow the published literature rather than marketing material.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
According to CTV News Queen's Park Bureau Chief, Colin D'Mello, Premier Ford removed Fedeli as Finance Minister on June 20, 2019 in the "wake of a disastrous budget rollout that's left the Progressive Conservative government drowning in negative publicity." Minister Fedeli tabled the Ford government's first budget on April 11, 2019. According to the Sault Star, Fedeli was demoted from "highly-touted finance post" and "blamed" for the "failure to sell voters on the $163.4-billion budget and the cost of breaking a 10-year deal that ultimately expands beer and wine sales in grocery stores, costing taxpayers $1 billion." NDP Timiskaming-Cochrane MPP, John Vanthof, said that the 2019 budget failed northern Ontario by not providing funds for Highway 69, the Ring of Fire, expanded broadband access, and cuts to Indigenous Affairs, Ministry of Natural Resources, the Ministry of Agriculture, Food, and Rural Affairs, and more. Vanthof said that there "will be beer in corner stores, drinks at 9 in the morning, tailgate parties, and blue licence plates, but when the fog is cleared, there is also an over $500 million cut to the Ministry of Northern Development and Mines." In the fiscal year 2019, the publicly funded Legal Aid Ontario will receive $133 million less than previously, representing a funding cut of 30 per cent, as part of the Ford government's deficit-cutting plan, presented in the April 2019 budget.
In one study, disk diffusion method proved concentration-dependent antifungal activity against Trichophyton, Microsporum and Epidermophyton, three of the most common species of dermatophytes that cause superficial fungal infections of human skin. Further research is needed, however, to examine the role of sangre de grado from Croton lechleri as an effective antifungal agent in animal and human models. Antiviral activity against influenza, parainfluenza, Herpes simplex viruses I and II, and Hepatitis A and B by Croton lechleri extracts and compounds have been exhibited. The most notable compound involved in antiviral activity is SP-303, also known as crofelemer, which has been heavily studied in vitro for its antiviral activity against the aforementioned viruses, as well as thymidine kinase mutants of HSV-1 and HSV-2 and acyclovir-resistant strains. Antidiarrhoeal Activity Crofelemer, a purified proanthocyanidin oligomer extracted from the sap of Croton lechleri has been investigated for potential antidiarrhoeal activity. Various clinical studies have confirmed significant improvement in acute E. coli and V. cholera diarrhea cases from the administration of crofelemer. In the context of the principal luminal membrane determinants of intestinal fluid secretion, the mechanism of crofelemer action involves the inhibition of apical membrane cAMP-stimulated (CFTR) and calcium-stimulated (CaCC) Cl− channels by crofelemer molecules, with little effect on cation channels or cAMP/calcium signaling.
=== Army service === In the U.S. Army, Jones took part in World War I in an all-Black unit until his mechanical skills were spotted, and he was promoted to sergeant working as an electrician and even teaching other soldiers. Jones performed the wiring necessary to equip his camp with electricity, telegraph, and telephone services.
Sources: en.wikipedia.org
=== Disadvantages === One disadvantage is that not all molecules are detectable. Because only molecules with a proton affinity higher than water can be detected by PTR-MS, proton transfer from H3O+ is not suitable for all fields of application. Therefore, in 2009 first PTR-MS instruments were presented, which are capable of switching between H3O+ and O2+ (and NO+) as reagent ions. This enhances the number of detectable substances to important compounds like ethylene, acetylene, most halocarbons, etc. Furthermore, particularly with NO+ it is possible to separate and independently quantify some isomers. In 2012 a PTR-MS instrument was introduced which extends the selectable reagent ions to Kr+ and Xe+; this should allow for the detection of nearly all possible substances (up to the ionization energy of krypton (14 eV)). Although the ionization method for these additional reagent ions is charge-exchange rather than proton-transfer ionization the instruments can still be considered as "classic" PTR-MS instruments, i.e. no mass filter between the ion source and the drift tube and only some minor modifications on the ion source and vacuum design. The maximum measurable concentration is limited. Equation (2) is based on the assumption that the decrease of reagent ions is negligible, therefore the total concentration of VOCs in air must not exceed about 10 ppmv. Otherwise the instrument's response will not be linear anymore and the concentration calculation will be incorrect. This limitation can be overcome easily by diluting the sample with a well-defined amount of pure air.
=== Discovery === Ritonavir (initially designated as ABT-538) was developed through the systematic structural modification of A-80987, a moderately potent, symmetry-based HIV protease inhibitor. While A-80987 demonstrated good oral bioavailability, its clinical utility was limited by a very short circulating half-life. This rapid clearance was primarily driven by the oxidative metabolism (specifically N-oxidation) of its pyridyl end groups by cytochrome P450 enzymes in the liver and intestine.
In terms of coregulator recruitment, the ratios of coactivators to corepressors vary in different tissues throughout the body, and it is thought that SARMs may have agonistic effects in tissues with an excess of coactivators relative to corepressors like muscle and bone and may have partially agonistic or antagonistic effects in tissues with an excess of corepressors over coactivators like the prostate. Another mechanism may be that SARMs like enobosarm induce the N/C interaction less readily than AR full agonists like DHT. Induction of the N/C interaction has been associated with the effects of endogenous and exogenous AR agonists, for instance virilization and prostate growth. In animal studies, enobosarm has shown potent muscle-promoting effects that were similar to those of testosterone and DHT. In one of the first published studies, enobosarm maximally restored prostate weight to 51%, seminal vesicle weight to 98%, and levator ani muscle weight to 136% in castrated male rats relative to gonadally intact control male rats, with an ED50 dose for muscle of 0.03 mg/day. For comparison, testosterone propionate was able to maximally stimulate levator ani muscle to 104% and prostate weight to 121%, with ED50 doses of 0.15 mg/day and 0.13 mg/day, respectively. Hence, enobosarm was able to stimulate the levator ani muscle to a size greater than that in normal male rats or produced with exogenous testosterone in castrated male rats, but was only capable of partially rescuing prostate gland weight.
Upregulation An increase in the number or sensitivity of receptors on a neuron, often in response to reduced stimulation or drug exposure. A mechanism of plasticity. Utricle A structure within the vestibular system that detects linear acceleration and head position relative to gravity. Works in tandem with the saccule. Uveitis Inflammation of the uveal tract (including the iris, ciliary body, and choroid), which can cause visual disturbances and is sometimes associated with autoimmune neurological disorders.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.